Company Description

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.

Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer.

The company was founded in 2003 and is headquartered in Miami, Florida.

Summit Therapeutics Inc.

Country	United States
Founded	2003
Industry	Biotechnology
Sector	Healthcare
Employees	159
CEO	Robert W. Duggan

Contact Details

Address: 601 Brickell Key Drive, Suite 1000 Miami, Florida 33131 United States
Phone	305 203 2034
Website	smmttx.com

Stock Details

Ticker Symbol	SMMT
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001599298
CUSIP Number	86627T108
ISIN Number	US86627T1088
Employer ID	37-1979717
SIC Code	2834

Key Executives

Name	Position
Dr. Mahkam Zanganeh D.D.S., M.B.A.	Co-Chief Executive Officer, President and Director
Robert W. Duggan	Co-Chief Executive Officer and Executive Chairman
Prof. Dame Kay Davies DBE, FRS CBE	Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
Bhaskar Anand	Chief Accounting Officer
Nathan LiaBraaten	Senior Director of Investor Relations
Dave Gancarz	Chief Business and Strategy Officer
Dr. Fong Clow	Chief Biometrics Officer

Latest SEC Filings

Date	Type	Title
Oct 29, 2025	S-3ASR	Automatic shelf registration statement of securities of well-known seasoned issuers
Oct 22, 2025	8-K	Current Report
Oct 20, 2025	10-Q	Quarterly Report
Oct 20, 2025	8-K	Current Report
Sep 8, 2025	8-K	Current Report
Aug 11, 2025	8-K	Current Report
Aug 11, 2025	8-K	Current Report
Aug 11, 2025	424B5	Filing
Aug 11, 2025	10-Q	Quarterly Report
Jun 20, 2025	8-K	Current Report

View All SEC Filings